MedTrace Logo

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

NCT01643590 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2014-02-07

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo controlled Phase II study is designed to assess the safety and efficacy of using JVS-100 to treat heart failure.

Conditions

  • Ischemic Heart Failure

Interventions

BIOLOGICAL

JVS-100 15 mg dose Injection

Intramyocardial Injection

BIOLOGICAL

Placebo Injection

Intramyocardial Injection

BIOLOGICAL

JVS-100 30 mg dose injection

Intramyocardial Injection

Sponsors & Collaborators

  • Juventas Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-10-31
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01643590 on ClinicalTrials.gov